Editor's key points † Morphine can influence migration and gene expression and the NET1 gene has a role in migration of cancer cells. † Morphine increased migration of cancer cells. † Silencing NET1 expression reversed the effect of morphine, despite the absence of the mu-opioid receptor. † The effect of morphine on NET1 gene expression may explain the effect of morphine on breast cancer cell migration.
analgesia techniques preserve effective perioperative immune defences, including natural killer T-lymphocyte activity against tumour progression by attenuating the surgical stress response and by sparing postoperative opioids. 14 However, morphine has been shown to have direct effects on cancer cell function essential for metastasis, specifically on their ability to proliferate, migrate, and invade, but with conflicting results from in vitro studies to date. 15 -19 Mechanisms of any direct effect of morphine on cancer cells also remain to be elucidated. For example, activation of opioid receptors with morphine was shown to exert an antiproliferative effect in one report, 15 but the peripheral opioid receptor antagonist methylnaltrexone has recently been demonstrated to exert anti-proliferative effects on human carcinoma cells in vitro.
Opioids can influence gene expression. It has been shown that a single injection of morphine can alter the expression of major groups of genes, including those responsible for cytoskeleton-related proteins, but whether this effect is mediated by standard opioid receptors is unknown. 21 Recent molecular analysis has shown that activation of a single gene, affecting a process essential for metastasis, can alone be sufficient to induce metastasis in vitro. 22 23 One such gene may be the NET1 gene, which has been identified through the Serial Analysis of Gene Expression (SAGE) database as overexpressed in breast and gastric adenocarcinoma cells. 24 25 The NET1 gene has a key role in organization of the actin cytoskeleton and thus in the ability of cancer cells to migrate and invade. 26 27 It has recently been shown that NET1 expression can help identify lymph nodepositive breast cancer patients at high risk of metastasis. 28 Therefore, we hypothesized that morphine may increase breast cancer cell migration and that this is mediated by the NET1 gene. Accordingly, we investigated whether the NET1 gene is expressed in oestrogen receptor-positive and oestrogen receptor-negative breast adenocarcinoma cell lines and if changes in NET1 gene expression resulted in altered cellular migration. We also investigated whether these cells express opioid receptors and any effect of morphine on NET1 gene expression, migration, and proliferation in both oestrogen receptor-positive and -negative breast adenocarcinoma cells, in addition to the effect of NET1 gene silencing.
Methods

Cell cultures
MDA-MB-231 is an oestrogen receptor-negative human breast adenocarcinoma cell line. Cells were cultured in L-Liebowitz 15 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, and 1% penicillin -streptomycin. MCF7 is an oestrogen receptor-positive human breast adenocarcinoma cell line. These cells were grown in Eagle's Minimum Essential Medium with Earle's salts and sodium bicarbonate, also supplemented with FBS, L-glutamine, and penicillin-streptomycin. Both cell lines were incubated at 378C, in humidified atmospheric air with 5% CO 2 . Cells were grown as monolayers in 75 cm 2 standard tissue culture dishes (Sarstedt, Ireland).
The medium was changed every 3 days, and passaged weekly. For experiments, cells were harvested from 70% subconfluent cultures. Chinese Hamster Ovary (CHO) cells were used as positive controls for opioid receptor expression. CHO cells expressing the human nociceptin/orphanin FQ (NOP) receptor were cultured in Dulbecco's modified Eagle medium/Ham's F12 medium (50:50) supplemented with 5% FBS, penicillin (100 IU ml 21 ), streptomycin (100 mg ml 21 ), and fungizone (2.5 mg ml
21
). Stock cultures were further supplemented with hygromycin B (200 mg ml
) and geneticin (200 mg ml
). CHO cells expressing the human kappa-opioid receptor (KOP), delta-opioid receptor (DOP), and mu-opioid receptor (MOP) were cultured in Ham's F12 medium with 10% FBS, with penicillin, streptomycin, and fungizone. Again, geneticin was added to stock cultures. CHO cells were grown at 378C, in humidified air with 5% CO 2 and were harvested when confluent.
Drug exposure
Morphine hydrochloride was obtained in its generic chemical form from Sigma (Sigma-Aldrich Ireland Ltd, Arklow, Ireland). It was further diluted in dimethyl sulphoxide (DMSO) to 10 mg ml 21 and stored at room temperature and protected from light. To control for any effects of DMSO, control cells were also treated with DMSO. Immediately before the experiment, morphine was diluted with cell media to 100, 75, 50, 25, and 10 ng ml 21 . These concentrations are similar to those obtained clinically during i.v. administration. 21 Lysophosphatidic acid (LPA, Sigma) is an established driver of RhoA activation and has been shown to stimulate RhoAmediated cytoskeletal rearrangement events. 29 Cells were exposed to 10 mM LPA in DMSO for 1, 2, and 4 h. After exposure, cells were harvested and used in experiments as described below.
Cell proliferation assay
Cell proliferation was determined using CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega Inc., Madison, WI, USA) according to the manufacturer's protocol. Cells were added to 96-well plates at a density of 50 000 cells per well, incubated for 24 h in a medium with FBS to allow attachment, followed by 24 h incubation in a serum-free medium. Morphine or DMSO was added to appropriate wells. The plates were incubated for 12, 24, and 36 h. Experiments were repeated three times in triplicate (n¼3). Proliferation is defined as an increase in the number of cells as a result of cell growth and division and was determined by the measuring change in absorbance at 490 nm resulting from proportion of living cells on a plate.
Cell migration assay
Cancer cell migration across a microporous membrane was assessed using the Chemotaxis 96-well Cell Migration Assay (Chemicon International, Billerica, MA, USA) according to the manufacturer's protocol. A total of 50 000 cells were seeded to each upper chamber of the 96-well plate. Morphine and DMSO (control) diluted in media with 10% FBS were added to both upper and lower chambers of the appropriate wells. Cell migration was quantified as the number of cells that migrated directionally through an 8 mm pore-size membrane into a lower chamber containing 150 ml of media with 20% FBS as chemoattractant. Migration was measured as fluorescence at 480/520 nm and was corrected for proliferation. Independent experiments were repeated three times in triplicate (n¼3).
RNA extraction and polymerase chain reaction
NET-1 expression RNA was isolated as previously described. 25 30 Total RNA (2 mg) was treated with DNAse I and reverse transcribed Direct effect of morphine on breast cancer cells using random hexamers and SuperScript II reverse transcriptase (Invitrogen Ltd, UK). Primers were designed using Primer3 software (http://frodo.wi.mit.edu/cgi-bin/primer3/ primer3_www.cgi) and synthesized by Sigma-Aldrich, Ireland. The sequences of primers used for polymerase chain reaction (PCR) are available in Supplementary Table  S1 . PCR was carried out in a 50 ml mix containing 0.5 ml of Taq polymerase (Invitrogen) and 1 ml of cDNA. PCR products were then run on 2% agarose gel with a parallel 100 bp DNA ladder (Promega, UK). Real-time PCR was carried out according to the manufacturer's instructions using the LightCycler RNA SYBR Green 1 Amplification Kit (Roche Applied Science). All measurements were independently repeated six times (n¼6) except NET1 expression after exposure to morphine (n¼3). The maximum concentration of total RNA template used was 0.5 mg ml 21 . Data are presented as cycle thresholds (C t ), and in quantitative analysis, the △△C t method was performed using the LightCycler version 4.0 software. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression levels were used to normalize NET1 expression.
Opioid receptor expression
Total RNA was isolated from the breast cancer cell lines and CHO cells (positive control) from confluent 25 cm 2 flasks using either standard Tri-reagent methodology or a preparatory RNA isolation kit (mirVana Applied Biosystems) which uses a combination of organic-and solid-phase extraction methodologies. 31 Final RNA samples were resuspended in PCR grade water. RNA mass was determined using an Eppendorf Biophotometer and the purity was assessed from the 260/280 nm ratio which was .1.8. Extracted RNA was processed using a Turbo DNA-free w kit to remove any residual genomic DNA (gDNA) contamination before reverse transcription and production of copy DNA (cDNA) using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Warrington, UK). cDNA samples were probed using quantitative PCR and using commercially available TaqMan w probes from Applied Biosystems, KOP (OPRK1, Hs00175127_m1), NOP (OPRL1-Hs00173471_m1), MOP (OPRM1, Hs01053957_m1), and DOP (OPRD1, Hs00538331_m1). GAPDH was used as an endogenous control. CHO GAPDH Taqman probes were custom designed using Applied Biosystems Custom Taqman Gene Expression Assay Service (Supplementary Table S1 ). The thermal profile for all Q-PCR reactions in the StepOne instrument (Applied Biosystems) was 2 min at 508C, 10 min at 958C, 50 cycles of 15 s at 958C, and 1 min at 608C. Non-template controls were included for all samples. Data are presented as cycle thresholds (C t ) and in quantitative analysis, △C t is based on the differences between GAPDH and the gene of interest; MOP, DOP, KOP, and NOP. Experiments were repeated five times.
Gene silencing of NET1 by RNA interference
Two siRNA duplexes were designed and synthesized for silencing the NET1 gene, as previously described (Qiagen Inc., CA, USA). 25 Sequences of duplexes are listed in Supplementary   Table S1 . A chemically synthesized non-silencing siRNA duplex that had no known homology with any mammalian gene was used to control for non-specific silencing events. Cells (3×10 5 ) were added to each well of a 6-well plate in 3 ml growth media and incubated under the standard conditions for 24 h. After incubation, media was removed from the cells and a mix was added of 2.4 ml growth medium with 5 mg siRNA, 500 ml buffer, and 30 ml RNAifect (ratio siRNA:RNAifect¼1:6) (Qiagen) dropwise. The cells were incubated for 48 h under standard conditions before assay/RNA extraction.
Statistical analysis
Data were summarized as median and inter-quartile range. Differences between paired groups (i.e. before vs after an experimental manipulation) and between different groups were evaluated using the Wilcoxon matched pairs test and the Kruskal-Wallis tests with post hoc Dunn's test, respectively, as appropriate. A P-value of ,0.05 was taken to indicate the statistical significance.
Results
NET1 expression in breast cancer cell lines
We performed these experiments to determine if the NET1 gene was expressed in the breast cancer cells lines and if expression was changed with LPA or siRNA, which would imply that it can also be changed with exposure to other effectors such as morphine. NET1 expression was detected in both MCF7 and MDA-MB-231 cells. The effect of cell exposure to LPA is shown in Table 1 . Treatment of cells with 10 mM LPA significantly increased expression of the NET1 gene in MCF7 by 2.9-fold [median cycle threshold (C t ) 26 .05] and in MDA-MB-231 cell line by 78-fold (median C t 23.06) after 2 h of incubation. Treatment with 10 mM LPA also caused a corresponding increase in migration by 234% 
Effect of morphine on proliferation and migration
Proliferation experiments were carried out to determine that the chosen concentrations of morphine were not lethal to cells, and to enable migration results to be controlled for any change in proliferation. Morphine increased proliferation in both cell lines, with a 10-31% increase in MCF7 and a 2-16% increase in MDA-MB-231 cells (Fig. 1A-C) . Morphine increased migration in both breast cancer cell lines. Migration was increased dose dependently by 17-27% in MCF7 and by 7-53% in MDA-MB-231 cells (Fig. 2) . 
Effect of morphine on NET1 expression
Treatment of breast cancer cells with morphine resulted in increased expression of the NET1 gene. A 1.2 -4.3-fold increase in expression was observed in MCF7 cells (P¼0.04) (mean C t 26.53-31.34), and a 2.1-6.7-fold increase in expression was observed in MDA-MB-231 cells (P¼0.003) (mean C t 22.91 -31.05) (Fig. 3A and B ). This corresponded with increased migration after incubation with morphine. However, when NET1 expression was silenced, morphine did not increase migration of cells in either of the cell lines ( Fig. 4A and B) . NET1 silencing on average decreased morphine-induced migration of MCF7 cells by 13%, the decrease being largest at 36% at 75 ng ml 21 (P¼0.019).
Expression of opioid receptors
In order to determine if the effects of morphine were due to activation of opioid receptor, we assessed the opioid receptor complement by PCR in both cell types. High △C t values (approaching 20) were measured for DOP in MDA-MB-231 cells and for MOP and KOP in both cell types (Table 3 ). This suggests that translation into active protein is unlikely. MCF-7 cells did express DOP with △C t values of 13. Interestingly, both MCF-7 and MDA-MB-231 expressed mRNA encoding the NOP receptor with MDA-MB-231 expressing 6.5-fold higher levels (P,0.05). High levels of expression of all targeted was seen in the CHO cells (positive controls) as expected. 
Discussion
This is the first study to our knowledge to investigate direct effects of morphine on breast adenocarcinoma cell function in vitro using two different cells lines of the same histological type but different metastatic potential (oestrogen receptor positive and negative). It is also the first experimental study to evaluate the role of the metastases-promoting NET1 gene in migration and proliferation of breast adenocarcinoma cells.
We have shown that morphine caused an overall increase in proliferation and migration of cell lines. This increase was more apparent in oestrogen receptor-negative MDA-MB-231 cells. The consistency of results in both cell lines convincingly suggests that morphine directly stimulates migration and proliferation of breast adenocarcinoma cells. However, there was no clear dose -response relationship. A previous study using MCF7 cell suggests that morphine stimulates angiogenesis and thus indirectly promotes tumour growth, 13 but this study did not investigate direct effects of morphine on cell proliferation or migration. In another study using MCF7 cells, an inhibitory effect of morphine on cell growth was observed to be dependent on stimulation of the cancer cells by 17b-estradiol. 17 When 17b-estradiol was removed, the effect of morphine on proliferation of cancer cells became positive. These, and our results, suggest interplay between opioids and oestrogen receptors in the regulation of breast cancer cell function, and would be consistent with the more pronounced effect of morphine on oestrogen receptor-negative cells in our study. It remains to be seen if the stimulatory effect of morphine on cell migration in vitro, observed in our present study, is translated clinically in terms of metastatic ability in vivo and hence into changes in the incidence of metastasis in breast cancer patients receiving non-opioid analgesia.
On the other hand, it is well known that the opioid system is one of the main inhibitory systems in the body. Morphine has been shown to induce cancer cell apoptosis in vitro in leukaemia cell lines, lung adenocarcinoma cell lines, and also in MCF7 breast adenocarcinoma cell lines 15 and cause inhibition of in vitro proliferation, migration, and invasion of some colon, pancreatic, and head and neck cancer lines. 15 17 Our data contradict these findings. Therefore, we determined the opioid receptor status of breast adenocarcinoma cells and found that the NOP receptor was expressed to a greater extent in oestrogen receptor-positive cells and DOP was expressed to a greater extent in oestrogen receptornegative cells. We believe that the target for morphine, MOP, was absent. This suggests a complex interplay of morphine on breast cancer cells that does not involve MOP activation and as such does not contradict the above findings. Interpretation of our findings is limited, since we do not know what may be happening at the protein level. However, the relative absence of mRNA is highly suggestive of the absence of protein. Morphine and other opioids may cross cell membranes. 21 We therefore investigated genetic control of the function of the cells in terms of migration. Direct effect of morphine on breast cancer cells
The NET1 gene has been identified as overexpressed in breast and gastric adenocarcinoma cells. 23 24 Furthermore, its expression can identify node-positive breast cancer patients at high risk for distant metastasis. 28 It has been
shown that it has a key role in organization of the actin cytoskeleton and thus in the ability of cancer cells to migrate. 26 27 30 In our study, when NET1 gene expression was stimulated with LPA, an established driver of RhoA activation, this was associated with enhanced migration in both breast cell lines, but to a much greater extent in oestrogen receptor-negative cells. On the other hand, when NET1 expression was silenced by incubating cells with siRNA, the expected decrease in cell migration was minimal, suggesting that the absence of NET1 does not affect baseline cell migration. Our results concur with the present knowledge on NET1 function in gastric adenocarcinoma cells. 30 Also, oestrogen receptor-negative breast cancer is known to have greater metastatic potential, which could explain the difference in the NET1 gene expression following LPA exposure in our two cell lines. It has been suggested that certain gene expressions are dependent on oestrogen receptor status, 24 which suggests that further studies are needed to determine a possible involvement of NET1 in a metastatic potential of oestrogen receptor-negative breast adenocarcinoma cells. We also found that morphine affects NET1 gene expression in breast adenocarcinoma cells and thus changes the cells' ability to migrate. Little is known so far on the effect of morphine on gene expression and the role of changes in gene expression in direct effects of drugs on cells. Pentobarbital, isoflurane, and propofol have been shown to affect gene expression in vivo. 32 It has also been shown that a single dose of morphine can alter expression of two major groups of genes: for proteins involved in mitochondrial respiration and for cytoskeleton-related proteins, 29 but it has not been determined if this change in gene expression causes a change in cell function.
In conclusion, our results have shown that morphine significantly increases expression of the NET1 gene in both cell lines. This corresponded to an increase in migration of cells incubated with morphine compared with controls. To investigate the link between the effect of morphine on NET1 gene expression and effect of morphine on cell migration further, we exposed cells with silenced NET1 gene to morphine. In cells with silenced NET1, the stimulating effect of morphine on migration was lost. These results indicate that NET1 is required for morphine to fully exert its direct effect on breast cancer migration. Further studies are needed to further elucidate the mechanistic pathway of direct morphine effect on cell migration, perhaps involving protein end-products of the NET1 gene.
